Latest Interviews
Showing 1–3 of 3 interview transcripts.
Clear all filters- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z7 min
a16z Podcast | Players and Paths for Healthcare Startups
Healthcare startups navigate a complex, multi-stage landscape by aligning their go-to-market strategies with either therapeutic, diagnostic, or tool-based verticals to overcome distinct regulatory and reimbursement hurdles. Founders must determine whether to pursue internal drug development or leverage non-exclusive licensing for platforms, as seen in the billion-dollar valuation success of Atomab or the industry dominance of Illumina. This approach requires immediately defining specific evidence needs, regulatory pathways, and payment entities to ensure viable product commercialization in a fragmented market.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.